BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
June 15, 2011
View Archived Issues
4SC Stock Plummets on Vidofludimus Miss in RA
Shares in 4SC AG dropped 36 percent June 8 on news that its orally available drug vidofludimus missed the primary endpoint of a Phase IIb trial in rheumatoid arthritis, dashing investor hopes of a near-term deal. (BioWorld International)
Read More
Ipsen Restructures to Focus on Peptides and Toxins
Read More
Heart Stem Cells Can Make New Muscle, Study Shows
Read More
Quintiles Takes Equity Stake in Kareus Therapeutics
Read More
New Leadership Takes Over at Embattled Agency
Read More
UK Government Funds Tumor Profiling Program
Read More
Other News To Note
Read More